

Supporting Information

Novel ^{64}Cu labeled RGD₂-BBN heterotrimers for PET imaging of prostate cancer

Ermelinda Lucente^{§#‡}, Hongguang Liu[§], Yang Liu[§], Xiang Hu[§], Enza Lacivita[#], Marcello Leopoldo^{#*}, Zhen Cheng^{§*}

[§] Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, California, 94305-5344 [#] Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona, 4, 70125, Bari, Italy [‡] Present Address: FARMALABOR SRL Stabilimento via Pozzillo, zona ind. - 76012 Canosa di Puglia (BT) – Italy

Journal: Bioconjugate Chemistry

Running Title: ^{64}Cu -RGD₂-PG₁₂-BBN for PET Imaging of Prostate Cancer

* Author to whom correspondence should be addressed




Figure S1. HPLC radiochromatograms of $^{64}\text{Cu-DOTA-RGD}_2\text{-PG}_{12}\text{-BBN}$ and $^{64}\text{Cu-NOTA-GA-RGD}_2\text{-PG}_{12}\text{-BBN}$.




Figure S2. Tumor/blood and tumor/muscle ratios for athymic male nude mice at 1 h after injection of ^{64}Cu -NODA-GA-RGD₂-PG₁₂-BBN (3.7 MBq, 100 μCi) with or without blocking dose of RGD₂, BBN, or RGD₂ plus BBN.